28.66
price up icon1.09%   0.31
pre-market  Pre-market:  28.84   0.18   +0.63%
loading
Pfizer Inc stock is currently priced at $28.66, with a 24-hour trading volume of 44.89M. It has seen a +1.09% increased in the last 24 hours and a +2.25% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $28.19 pivot point. If it approaches the $28.80 resistance level, significant changes may occur.
Previous Close:
$28.35
Open:
$28.78
24h Volume:
44.89M
Market Cap:
$162.40B
Revenue:
$55.09B
Net Income/Loss:
$-309.00M
P/E Ratio:
15.66
EPS:
1.83
Net Cash Flow:
$5.11B
1W Performance:
+3.47%
1M Performance:
+2.25%
6M Performance:
+0.92%
1Y Performance:
-20.43%
1D Range:
Value
$28.42
$29.23
52W Range:
Value
$25.20
$37.80

Pfizer Inc Stock (PFE) Company Profile

Name
Name
Pfizer Inc
Name
Phone
(212) 733-2323
Name
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Employee
88,000
Name
Twitter
@Pfizer
Name
Next Earnings Date
2024-05-01
Name
Latest SEC Filings
Name
PFE's Discussions on Twitter

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Oct-20-23 Resumed UBS Neutral
Oct-16-23 Upgrade Jefferies Hold → Buy
Jul-17-23 Reiterated JP Morgan Neutral
Jul-14-23 Initiated HSBC Securities Buy
Jun-29-23 Downgrade Credit Suisse Outperform → Neutral
May-11-23 Downgrade Daiwa Securities Outperform → Neutral
Mar-06-23 Initiated Jefferies Hold
Feb-07-23 Upgrade Daiwa Securities Neutral → Outperform
Jan-26-23 Downgrade UBS Buy → Neutral
Jan-17-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-04-23 Downgrade BofA Securities Buy → Neutral
Dec-13-22 Upgrade Goldman Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
May-23-22 Initiated SVB Leerink Mkt Perform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Jan-05-22 Upgrade BofA Securities Neutral → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-20-21 Reiterated Cowen Outperform
Dec-17-21 Initiated Goldman Neutral
Dec-13-21 Upgrade UBS Neutral → Buy
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Outperform
Jul-27-21 Resumed Truist Buy
May-06-21 Downgrade Mizuho Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Feb-04-21 Upgrade DZ Bank Hold → Buy
Dec-16-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-20 Resumed Goldman Neutral
Nov-10-20 Resumed Bernstein Mkt Perform
Oct-12-20 Downgrade Atlantic Equities Overweight → Neutral
Sep-29-20 Initiated Berenberg Hold
Jun-16-20 Initiated SVB Leerink Mkt Perform
Feb-27-20 Initiated Barclays Equal Weight
Feb-27-20 Upgrade Standpoint Research Hold → Buy
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Outperform
Oct-17-19 Resumed BofA/Merrill Neutral
Jul-30-19 Downgrade BofA/Merrill Buy → Neutral
Jul-30-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-19 Resumed Morgan Stanley Overweight
Feb-20-19 Resumed Citigroup Neutral
Jan-31-19 Upgrade Argus Hold → Buy
Jan-31-19 Upgrade Credit Suisse Neutral → Outperform
Jan-23-19 Downgrade UBS Buy → Neutral
Dec-11-18 Downgrade JP Morgan Overweight → Neutral
Nov-01-18 Downgrade BMO Capital Markets Outperform → Market Perform
View All

Pfizer Inc Stock (PFE) Financials Data

Pfizer Inc (PFE) Revenue 2024

PFE reported a revenue (TTM) of $55.09 billion for the quarter ending March 31, 2024, a -40.86% decline year-over-year.
loading

Pfizer Inc (PFE) Net Income 2024

PFE net income (TTM) was -$309.00 million for the quarter ending March 31, 2024, a -101.06% decrease year-over-year.
loading

Pfizer Inc (PFE) Cash Flow 2024

PFE recorded a free cash flow (TTM) of $5.11 billion for the quarter ending March 31, 2024, a -74.73% decrease year-over-year.
loading

Pfizer Inc (PFE) Earnings per Share 2024

PFE earnings per share (TTM) was -$0.06 for the quarter ending March 31, 2024, a -101.18% decline year-over-year.
loading

Pfizer Inc Stock (PFE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BOURLA ALBERT
Chairman & CEO
Feb 23 '24
Option Exercise
27.34
127,674
3,490,607
439,748
LANKLER DOUGLAS M
Executive Vice President
Feb 23 '24
Option Exercise
27.34
95,755
2,617,942
230,920
SUSMAN SALLY
Executive Vice President
Feb 23 '24
Option Exercise
27.34
63,837
1,745,304
218,148
JOHNSON RADY A
Executive Vice President
Feb 23 '24
Option Exercise
27.34
29,436
804,780
123,073
McDermott Michael
Executive Vice President
Feb 23 '24
Option Exercise
27.34
12,412
339,344
95,408
SAHNI PAYAL
Executive Vice President
Feb 23 '24
Option Exercise
27.34
11,527
315,148
34,604
BOSHOFF CHRISTOFFEL
Executive Vice President
Feb 23 '24
Option Exercise
27.34
9,752
266,620
148,703
DAMICO JENNIFER B.
SVP & Controller
Feb 23 '24
Option Exercise
27.34
9,752
266,620
19,228
Gottlieb Scott
Director
Dec 15 '23
Buy
26.47
3,000
79,401
9,000
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
$325.09
price up icon 1.06%
drug_manufacturers_general SNY
$51.21
price up icon 0.35%
drug_manufacturers_general NVS
$110.50
price up icon 0.51%
$69.97
price up icon 1.77%
drug_manufacturers_general BMY
$40.75
price down icon 0.90%
Cap:     |  Volume (24h):